Top-News
Biotechnologie USA

Ideaya Bioscience Inc Aktie

Aktie
WKN:  A2PJPB ISIN:  US45166A1025 US-Symbol:  IDYA
21,38 $
+0,91 $
+4,45%
18,875 € 17:35:24 Uhr
Depot/Watchlist
Aktienanzahl *
74,56 Mio.
Marktkapitalisierung *
1,32 Mrd. €
Streubesitz
-
Index-Zugehörigkeit
-
IR-Website
zur Website
*Stand: 07.03.2024

Ideaya Bioscience Inc News

28.04.25 - PR Newswire
IDEAYA Biosciences to Participate in Upcoming May 2025 Investor Relations Events
IDEAYA Biosciences to Participate in Upcoming May 2025 Investor Relations Events PR Newswire
25.04.25 - PR Newswire
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) PR Newswire
14.04.25 - PR Newswire
IDEAYA Biosciences Announces Successful FDA Type D Meeting on Phase 3 Registrational Trial Design for Darovasertib as Neoadjuvant Therapy for Primary Uveal Melanoma
IDEAYA Biosciences Announces Successful FDA Type D Meeting on Phase 3 Registrational Trial Design for Darovasertib as Neoadjuvant Therapy for Primary Uveal Melanoma PR ...
10.04.25 - PR Newswire
IDEAYA Biosciences Announces Phase 1/2 Expansion for IDE397 and Trodelvy® Combination in MTAP-Deletion Urothelial Cancer
IDEAYA Biosciences Announces Phase 1/2 Expansion for IDE397 and Trodelvy® Combination in MTAP-​Deletion Urothelial Cancer PR Newswire
01.04.25 - PR Newswire
IDEAYA Biosciences Announces Participation in Upcoming April 2025 Investor Relations Events
IDEAYA Biosciences Announces Participation in Upcoming April 2025 Investor Relations Events PR Newswire
31.03.25 - PR Newswire
IDEAYA Biosciences Receives US FDA Breakthrough Therapy Designation for Darovasertib Monotherapy in Neoadjuvant Uveal Melanoma
IDEAYA Biosciences Receives US FDA Breakthrough Therapy Designation for Darovasertib Monotherapy in Neoadjuvant Uveal Melanoma PR Newswire
28.03.25 - PR Newswire
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) PR Newswire
26.03.25 - PR Newswire
IDEAYA Announces Oral Presentation at the New Drugs on the Horizon Series at AACR 2025 for IDE275 (GSK959), a Phase 1 Werner Helicase Inhibitor
IDEAYA Announces Oral Presentation at the New Drugs on the Horizon Series at AACR 2025 for IDE275 (GSK959), a Phase 1 Werner Helicase Inhibitor PR Newswire
03.03.25 - PR Newswire
IDEAYA Biosciences Announces Collaboration with ATTMOS to Accelerate AI/ML-Enabled Drug Discovery for Unprecedented First-in-Class Oncology Targets
IDEAYA Biosciences Announces Collaboration with ATTMOS to Accelerate AI/ML-​Enabled Drug Discovery for Unprecedented First-​in-Class Oncology Targets PR Newswire
28.02.25 - PR Newswire
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) PR Newswire
13.02.25 - PR Newswire
IDEAYA Biosciences, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
IDEAYA Biosciences, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update PR Newswire
13.02.25 - PR Newswire
IDEAYA Announces Further Gilead Sciences Clinical Study Collaboration Evaluating Combination of Trodelvy® and IDE397 in MTAP-Deletion NSCLC
IDEAYA Announces Further Gilead Sciences Clinical Study Collaboration Evaluating Combination of Trodelvy® and IDE397 in MTAP-​Deletion NSCLC PR Newswire
10.02.25 - PR Newswire
IDEAYA Biosciences Announces Appointment of Healthcare Investment Banking Veteran Joshua Bleharski as Chief Financial Officer
IDEAYA Biosciences Announces Appointment of Healthcare Investment Banking Veteran Joshua Bleharski as Chief Financial Officer PR Newswire
31.01.25 - PR Newswire
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) PR Newswire
27.01.25 - PR Newswire
IDEAYA Biosciences to Participate in Upcoming February 2025 Investor Relations Events
IDEAYA Biosciences to Participate in Upcoming February 2025 Investor Relations Events PR Newswire
12.01.25 - PR Newswire
IDEAYA Biosciences Announces Participation at the 43rd Annual J.P. Morgan Healthcare Conference and 2025 Corporate Guidance
IDEAYA Biosciences Announces Participation at the 43rd Annual J.P. Morgan Healthcare Conference and 2025 Corporate Guidance PR Newswire
29.12.24 - PR Newswire
IDEAYA Biosciences Enters Exclusive License with Hengrui Pharma for SHR-4849, a Novel Phase 1 DLL3 Topo-I-Payload ADC Targeting SCLC and NET Solid Tumors
IDEAYA Biosciences Enters Exclusive License with Hengrui Pharma for SHR-4849, a Novel Phase 1 DLL3 Topo-​I-Payload ADC Targeting SCLC and NET Solid Tumors PR Newswire
27.12.24 - PR Newswire
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) PR Newswire
17.12.24 - PR Newswire
IDEAYA Announces IDMC Recommendation of Move-Forward Dose in Part 2a of Registration-Enabling Trial of Darovasertib and Crizotinib Combination in 1L HLA-A2-Negative Metastatic Uveal Melanoma
IDEAYA Announces IDMC Recommendation of Move-​Forward Dose in Part 2a of Registration-​Enabling Trial of Darovasertib and Crizotinib Combination in 1L HLA-A2-Negative ...
16.12.24 - PR Newswire
IDEAYA Announces Development Candidate Nomination of IDE251, a Potential First-in-Class KAT6/7 Dual Inhibitor Targeting 8p11 Amplification Tumors in Breast and Lung Cancers
IDEAYA Announces Development Candidate Nomination of IDE251, a Potential First-​in-Class KAT6/7 Dual Inhibitor Targeting 8p11 Amplification Tumors in Breast and Lung ...

Newssuche

Videos

newspaper
30.04.25 +13,48%
Technical Trading: Cotton Long Chance
Cotton Long Typ: Turbo Open End WKN: VP6N8D Hebel: 3,80 Laufzeit: OpenEnd Einstieg: Market ... Mehr »